Particularly for children under 3 years who cannot receive radiotherapy, PD-L1-related immune checkpoint inhibitors may be able to delay tumor recurrence to buy time for radiotherapy and further improve the outcomes of these patients. This evidence concerns the gene CD274 and neoplasm.